Betterlife Pharma Inc Stock Price, News & Analysis

BetterLife Pharma announced the appointment of Dr. Thomas Laughren as a Regulatory Advisor. Dr. Laughren, a former FDA Director of Psychiatry Products, brings extensive experience in psychiatric drug development. CEO Dr. Ahmad Doroudian expressed excitement about this addition, noting it will enhance their IND-enabling activities. BetterLife focuses on developing second-generation psychedelics for neuro-psychiatric disorders, alongside interferon-based technologies targeting viral infections like COVID-19.

BetterLife Pharma Inc. announced its inclusion in the Horizons Psychedelic Stock Index ETF, providing significant exposure to investors in the psychedelics sector. The Company closed a non-brokered private placement, issuing 1,779,833 common shares at CAD$1.40 each, raising CAD$2,491,766 for working capital and its therapeutic pipeline, which includes TD-0148A, a second-generation LSD derivative aimed at treating severe depression, PTSD, and migraines. CEO Ahmad Doroudian highlighted the ETF's potential to attract new investors and enhance shareholder value.

BetterLife Pharma has announced a research agreement with the laboratory of Dr. Adam L. Halberstadt at UCSD to explore TD-0148A, a non-hallucinogenic derivative of LSD, for the treatment of severe treatment-resistant depression and PTSD. The collaboration aims to leverage Dr. Halberstadt's expertise in psychedelic pharmacology to evaluate TD-0148A's potential in preclinical behavioral studies. This development aligns with BetterLife's focus on addressing the unmet needs in mental health treatments, reflecting a strategic push into innovative therapeutic solutions.

BetterLife Pharma Inc. announced a partnership with Pontificia Universidad Católica de Chile to initiate a randomized, placebo-controlled trial named IN2COVID in Q2 2021. The study aims to evaluate the effectiveness of Altum Pharmaceuticals' inhaled interferon alpha-2b product, AP-003, in treating COVID-19 patients. Preclinical studies suggest that interferon alpha-2b may enhance viral clearance. The trial will consist of two phases: a Phase 1 trial in healthy subjects and a Phase 2 trial in early-stage COVID-19 patients, potentially concluding by Q3 2021.

BetterLife Pharma Inc. has partnered with Carleton University to research TD-0148A, a novel LSD derivative aimed at treating mental health disorders like severe depression and PTSD. This second-generation molecule is designed to deliver therapeutic effects without the psychoactive side effects typical of traditional LSD. The collaboration leverages Carleton's expertise in neuroscience to accelerate the research process and potentially bring this therapy to clinical trials. The company's focus aligns with addressing the significant unmet needs in psychiatric treatment.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) announced a partnership with Eurofins CDMO Alphora Inc. for GMP manufacturing of its second-generation LSD derivative, TD-0148A. This treatment aims to address major depressive disorders while minimizing psychoactive side effects. The manufacturing takes place in Mississauga, Ontario, utilizing a proprietary process that avoids controlled substances. Dr. Ahmad Doroudian emphasized the significance of this collaboration for rapidly advancing the drug's development towards regulatory submission.

BetterLife Pharma has announced its participation in the Emerging Growth Conference on February 17, 2021, inviting individual and institutional investors to a real-time, interactive presentation. The company's CEO, Dr. Ahmad Doroudian, will present BetterLife’s plans at 2:30 PM Eastern for 30 minutes, followed by a Q&A session. The event allows for direct interaction with shareholders and the investment community. An archived version will be available post-event. For more details, visit BetterLife's website.

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) has engaged Pharmaceutical Solutions Ltd. as its Clinical Research Organisation for an upcoming clinical trial of AP-003, an inhaled interferon treatment for mild to moderate COVID-19 cases. Set to begin in late 2020 across various Australian sites, the trial will involve 150 participants and assess the effectiveness of AP-003 compared to a placebo. This randomized, double-blind study aims to explore the potential of AP-003 in mitigating COVID-19 symptoms and reducing hospital admissions, marking a significant step in the global fight against the pandemic.

BetterLife Pharma Inc. has partnered with VirTrial, LLC to enhance patient monitoring for its upcoming COVID-19 clinical trials in Australia, focusing on the proprietary formulation AP-003. This collaboration enables virtual visits via a secure telehealth platform, facilitating patient recruitment and retention amidst travel restrictions. The company has also signed a share purchase agreement to assign its subsidiary, Pivot Pharmaceuticals Manufacturing Corp., including its Quebec facility lease. This strategic move aims to streamline operations and focus on advancing clinical research.